Clementia Pharmaceuticals, Inc.
(NASDAQ : CMTA)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson 0.58%149.060.7%$734.24m
BMYBristol-Myers Squibb Co. -0.08%66.731.0%$726.64m
PFEPfizer Inc. -0.25%40.510.9%$611.72m
MRKMerck & Co., Inc. -0.22%90.980.7%$577.92m
ABBVAbbVie, Inc. -1.40%88.012.3%$545.73m
LLYEli Lilly & Co. -1.29%139.611.1%$400.65m
APLSApellis Pharmaceuticals, Inc. 0.30%40.500.0%$107.43m
NVSNovartis AG 0.88%95.940.2%$101.60m
AZNAstraZeneca Plc 1.62%51.331.2%$98.49m
GSKGlaxoSmithKline Plc 1.55%47.890.2%$84.36m
KRTXKaruna Therapeutics, Inc. 9.17%104.520.0%$68.78m
SNYSanofi 0.10%51.240.2%$68.67m
NVONovo Nordisk A/S -0.02%61.300.1%$64.41m
RETAReata Pharmaceuticals, Inc. -2.24%211.433.5%$64.03m
TPTXTurning Point Therapeutics, Inc. 2.72%59.950.0%$40.48m

Company Profile

Clementia is a biopharmaceutical company dedicated to bringing effective new treatments to people who have none. Clementia is rapidly developing its first lead product candidate, palovarotene, to treat fibrodysplasia ossificans progressiva (FOP), an ultra-rare and severely disabling disorder, and other diseases.